6 hours Ago By Defense World Staff
Maxim Group began coverage on shares of BioHarvest Sciences ( NASDAQ:BHST – Free Report ) in a research note published on Wednesday, Marketbeat reports. The brokerage issued a buy rating and a $12.00 price target on the stock.
Separately, HC Wainwright initiated coverage on BioHarvest Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $14.00 price objective for the company.
View Our Latest Stock Analysis on BHST BioHarvest Sciences Price Performance BioHarvest Sciences Company Profile ( Get Free Report ) BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. Further Reading Five stocks we like better than BioHarvest Sciences What Are Earnings Reports? Opal Fuels CEO on Steering the Future of Renewable Natural Gas Business Services Stocks Investing MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win EV Stocks and How to Profit from Them 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
